-
Cell Death Dis: ASC regulates the stability of HIF-1 alpha to induce the metastasis of squamous cell carcinoma in the mouth.
Time of Update: 2020-09-24
the study revealed that HIF-1 alpha was involved in asC-induced tumor metastasis.
researchers identified 195 genes associated with cellular movement that were highly SAS_ASC in ASC-expressed cells.
further studies showed that the initiators of these 14 ASC-induced highly expressed genes all contained a binding base sequence of the transcriptional regulator HIF-1 alpha.
-
National Science Review: Liu Sijin/Zheng Nanfeng has developed a new approach that has important treatment prospects for breast cancer metastasis.
Time of Update: 2020-09-24
study showed significant damage to EMT in breast cancer cells after PdPL treatment, in part because of inhibition of the transmission of the conversion growth factor-beta (TGF-beta).
-
Cell Death Dis: Powerful herbal formula SH003 activates the autophagy cell death process for stomach cancer.
Time of Update: 2020-09-24
addition, these results show that in hypoxia, SH003-induced endocystic network stress response can regulate the autophagy cell death process induced by BNIP3 by inhibiting the STAT3-G9a path pathline.
, SH003 therapy may be an important cancer treatment strategy under hypoxia-mediated chemotherapy resistance.
-
Genome Medicine: Reveals the important role of non-coded RNA in the progression of non-small cell lung cancer and tumor immunity.
Time of Update: 2020-09-24
Long non-coding RNA (lncRNA) is extremely complex in the occurrence and metastasis of various types of cancer. , the detailed molecular mechanism of lncRNA in non-small cell lung cancer (NSCLC) is not
-
Fuhong Hanxuan Beval bead single anti-listing registration application was accepted by NMPA.
Time of Update: 2020-09-24
Recently, Fu Hong Hanxuan submitted on the Beval Pearl single anti-injection HLX04 (recombinant anti-VEGF humanized monoclonal antibody injection) listing application was officially accepted by the State Drug Administration (NMPA).
-
Nature: Scientists find key to 'stopping' cancer cells - TRIM37 or cell division 'inverter'
Time of Update: 2020-09-24
An article by scientists at Hopkins University, entitled Target TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer, kills certain human breast cancer cells by selectively attacking the core of the cell division mechanism, providing new inspiration for our search for drugs that destroy cancer cells without harming healthy cells.
-
Grail, a genetic sequencing giant that has financed more than $2 billion in cancer diagnosis, has applied for a listing.
Time of Update: 2020-09-24
According to its prospectos, Grail plans to launch a commercial cancer screening test called Gallei in 2021, which will be developed in a laboratory-developed manner before seeking full FDA approval, and estimates that its early screening technology will detect nearly 70 percent of fatal cancers within five years.
-
Clin Cancer Res: Ribociclib-Fluvis Group-PI3K inhibitors to treat HR-advanced breast cancer.
Time of Update: 2020-09-24
The study was an open-label, multi-center IB trial that recruited 70 post-menopaus HR-HER2-ABC patients to treat Rebosini (1/day, 3 weeks off for one week) and rybosinib, rebosini (continuous medication) and fluvis, rebosini, alpelisib, fluorovis, or rebosini and buparisib.
-
The European Union has approved the first-line treatment of imfinzi (durvalumab) for the widespread treatment of small cell lung cancer.
Time of Update: 2020-09-24
recently, AstraZeneca's Durvalumab has been approved by the European Union to treat adult patients with ES-SCLC with a variety of chemotherapy drugs.
The first immunotherapy in patients with widespread small cell lung cancer that improves both survival and response rates," said Dave Fredrickson, executive vice president of Oncology at AstraZeneca.
-
The cancer came twice, and she won twice! How can I avoid cancer again? The doctor pointed out two keys.
Time of Update: 2020-09-24
Cancer patients again cancer is 11 times more clinical than the general population, the incidence of secondary primary tumors is 11 times higher than the healthy population, the first treatment, lifestyle and genetic factors and other reasons, all affect the production of secondary tumors.
-
About 70% of the original study, Sorafeini domestic first imitation price announced.
Time of Update: 2020-09-24
Recently, according to the Inner Mongolia Autonomous Region pharmaceutical centralized procurement network issued a notice that Jiangxi Shanxiang Pharmaceutical Toluene Sulfini tablets (specification: 0.2g x 60 tablets) to give supplementary hanging network, the purchase price of 3990.00 yuan / box, September 5, 2020 officially implemented.
-
China County Health Conference: Wu Yiling academician team of Chinese medicine research and innovation results to help the prevention and treatment of primary-level chronic diseases.
Time of Update: 2020-09-24
From September 4th to 6th, the China County Health Conference was held in Suzhou, and the leaders of the relevant departments of the National Health and Health Commission, academicians from various di
-
BMJ: Use of hair dyes in women and risk assessment of tumors.
Time of Update: 2020-09-24
In addition, the risk of death from most specific tumors in people who have used hair dyes (including skin squamous cell carcinoma, bladder cancer, melanoma, estrogen-positive breast cancer, progesterone-positive breast cancer, hormone-positive breast cancer, brain cancer, colorectal cancer, kidney cancer, lung cancer and most blood cancers) or cancer-related deaths (n=4860;0.96) has not been significantly increased.
-
First-time U.S. Con completed the Pre-A round of financing to accelerate the market transformation of tumor molecular diagnostic products.
Time of Update: 2020-09-24
It is learned that YousanKang was founded in 2015, by the Sino-AMERICAN team of scientists and entrepreneurs co-founded, the company mainly focuses on in-body molecular diagnosis, product development, production, marketing and services as a whole, has built a complete industrial chain in the field of molecular diagnostics.
-
Inventory: A selection of Blod research on September 10, 2020.
Time of Update: 2020-09-24
2: The efficacy of human-sourced Fc-binding anti-CD3 monoclonal antibodies in T-ALL https://doi.org/10.1182/blood.2019003801T cell acute lymphoblastic leukemia (T-ALL) is an invasive malignancies, accounting for about 20% of ALL cases.
-
Sci Transl Med: Is the lysovirus "strong combination" with CAR T therapy that promises to cure solid tumors?
Time of Update: 2020-09-24
results showed that the lysovirus was able to transmit the antigen, CD19t, to the tumor and induce anti-tumor activity mediated by CD19-CAR T cells.
-
Nat Commun: DOT1L regulates the stability of AR and MYC in prostate cancer.
Time of Update: 2020-09-24
sensitivity of AR-positive cells is mainly due to the combination of AR and DOT1L on the far-end K79 methylation marker enhancer of the MYC gene, which does not exist in AR-negative cells.
, DOT1L selectively regulates the tumor-likeity of AR-positive prostate cancer cells, suggesting that it may be a potential therapeutic target for PCa.
-
Regent Bio has reached a strategic partnership with Jess Inda to conduct clinical studies on PD-1 single-anti-joint ERK inhibitor JSI-1187.
Time of Update: 2020-09-24
JSI-1187 is a selected ERK1/2 small molecule inhibitor developed by Jesinta, which is highly inhibitory to tumors with MAPK path pathfectal mutations in preclinical models, and is currently undergoing Phase I clinical trials in the United States, covering BRAF V600 mutant late malignant solid tumors, as well as adaptations such as RAMK mutation late malignant solid tumors, including RAS.
-
Nat Commun: Two large queues identified the same genetic risk of cancer.
Time of Update: 2020-09-24
recently, researchers published a paper in the journal Nature Communications, reporting that they conducted a genome-wide association study (GWAS) and a comprehensive assessment of genetic and polymorphisms of 18 cancer types in two large, population-based queues.
-
JAMA Network Open: The relationship between chemotherapy and thoracic fractures in patients with esophageal cancer.
Time of Update: 2020-09-24
Such as preoperative chemotherapy (CRT), local late-stage non-small cell lung cancer radiotherapy, and stereotactic radiation therapy of spinal tumors, the cumulative incidence of vertebral fractures in 1 to 2 years was 8% to 19%.
